GHRH antagonists exert their antitumor activity by binding to GHRH-R and SV1, thereby disrupting the autocrine/paracrine mitogenic signaling mediated by tumor-derived GHRH, IGF1, and IGF2 [18,20,38]. The gene discussed is GHRHR; the disease is neoplasm.